ASND实时信号 | 通过Getagraph.com最大化利润

购买 7254 min ago

@ $144.01

发出时间: 24 Apr 2024 @ 21:31

回报率: -2.21%

上一信号: Apr 23 - 01:18

上一信号: 出售

回报率: 0.54 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:26):

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD)...

Stats
今日成交量	24 175.00
平均成交量	352 706
市值	7.97B
EPS	$0 ( 2024-04-25 )
下一个收益日期	( $-1.570 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.39
ATR14	$0.320 (0.23%)

音量相关性

長: -0.02 (neutral)

短: 0.89 (strong)

Signal:(67.213) Same movement expected

Ascendis Pharma A/S 相关性

10 最正相关
LMPX	0.937
ATHN	0.927
ASRV	0.906
WABC	0.903
FLIC	0.9
JRJC	0.899
NFBK	0.896
ISTR	0.896
BCBP	0.894
USCB	0.892

10 最负相关
BMEA	-0.955
TMTS	-0.938
CLXT	-0.936
INZY	-0.927
ALDX	-0.925
ATVI	-0.924
SMFL	-0.913
CREX	-0.901
COCO	-0.899
RIVE	-0.898

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Ascendis Pharma A/S 相关性 - 货币/商品

-0.64
( weak negative )

-0.67
( moderate negative )

0.40
( neutral )

-0.70
( moderate negative )

0.50
( weak )

0.26
( neutral )

Ascendis Pharma A/S 财务报表

Annual	2023
营收:	$266.72M
毛利润:	$222.32M (83.36 %)
EPS:	$-8.55

FY	2023
营收:	$266.72M
毛利润:	$222.32M (83.36 %)
EPS:	$-8.55

FY	2022
营收:	$51.17M
毛利润:	$39.04M (76.28 %)
EPS:	$-10.40

FY	2021
营收:	$7.78M
毛利润:	$4.26M (54.71 %)
EPS:	$-7.00

Financial Reports:

No articles found.

Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

实时更新： Ascendis Pharma A/S [ASND]

Upcoming Earnings Alert